CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 92 enrolled
Drug / intervention
Dexmedetomidine +4 moredrug
Likely dose
Propofol 0.7 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04062123
NCT04062123Phase 1Completed

Modulation of Memory and Conditioning by Pain During Sedation With Anesthetics

Keith M Vogt·interventional·Posted Aug 20, 2019·Updated Apr 18, 2025

In Brief

A Phase 1 clinical trial evaluating Dexmedetomidine, Propofol, and 3 other interventions for Anesthesia and Pain. Completed, enrolled 92 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of pain on long-term memory and conditioned physiologic responses in the presence and absence of distinct intravenous anesthetics. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena The study will occur over 5 visits and involves no long-term follow up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Pain
CountriesUnited States

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 20, 2019
Enrollment StartJul 30, 2020
Primary CompletionApr 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.9 years ago

Interventions

Dexmedetomidinedrug

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Propofoldrug

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Fentanyldrug

Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

Peripheral Nerve Stimulationdevice

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

Placebodrug

Crystalloid IV solution will be infused, with no active drug.